China's Challenges in Implementing Compulsory Drug Patent Licenses and its Response in the Context of COVID-19

Abstract

Covid-19 has spread quickly throughout China and the entire world. According to the World Health Organization, there is a public health emergency that is of global significance (WHO). Controlling the drug supply is essential since this hazardous pandemic has seriously jeopardized global public security. This essay starts by looking at the current condition of COVID-19, analyzes the requirements for required drug patent licensing in different countries, points out the problems with mandatory drug patent licensing in China, and finally offers practical suggestions for forced pharma patent licensing. China and the rest of the world have experienced rapid Covid-19 spread. There is an international public health emergency, according to the World Health Organization (WHO). The majority of China's pharmaceutical companies were founded relatively recently, and they are currently producing copycat medications. The government needs to properly understand the value of the compulsory patent licensing system and offer the necessary support to ensure a successful rollout. The government can implement specific policies, add a special fund for drug development, offer loans to pharmaceutical companies, hire qualified staff for drug research and development, and generally strengthen China's pharmaceutical industry. Pharmaceutical companies are the manufacturers of drugs under the obligatory patent licensing system. Pharmaceutical companies should develop their overall strength, increase their ability to produce drugs, and have enough resources to meet social requirements and guarantee public health and safety. To increase the rate of development, it is vital to promote international collaboration and actively introduce foreign innovative systems and industrial facilities.